|
The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News: ---------- GENinCode PLC - Oxford-based genetic testing company focused on cardiovascular disease and ovarian cancer - Warns of full-year revenue below expectations, despite on-year growth. Pretax loss for the six months ended June 30 widens to £3.0 million from £2.4 million the previous year. Revenue rises 15% to £1.6 million from £1.4 million, led by the Spanish division, where first-half sales advance to £1.0 million from £912,000. Adjusted earnings before interest, taxation, depreciation and amortisation amount to a loss of £2.1 million, broadly stable on-year. Attributable loss per share narrows to 1.19 pence from 1.37p. The firm lowers annual revenue guidance to around £3.3 million ‘with similar levels of cost in the second half’. It still expects growth on-year, albeit less marked than the ‘significant increase’ it implied back in June, when it posted £2.7 million in revenue for 2024. GENinCode notes ‘slower than expected growth’ in NHS contract business as a result of restructuring. The firm also points to delays in securing a De Novo risk classification from the US Food & Drug Administration for its Cardio inCode-Score test. It aims to submit a De Novo application in the first quarter of 2026, and says discussions with possible commercial partners continue. ---------- Genflow Biosciences PLC - London-based biotechnology firm, with research facilities in Belgium - Posts a wider pretax loss but pegs its hopes on 2026 being a ‘pivotal’ year. Pretax loss widens to £737,618 during the first half of 2025 from £524,259 a year earlier, as Genflow books a £31,075 loss on currency translations, widened from £8,652 the previous year, while operating income declines to £245,107 from £792,109. The firm maintains having made ‘important progress’ in both its human and animal health segments, noting ‘approvals of two new therapies including GLP-1 agonists’ for patients with metabolic dysfunction-associated steatohepatitis. Within the next five months, it expects initial trial data for the use of its SIRT6 treatment in ageing canines. ---------- Ovoca Bio PLC - Dublin-based biopharmaceutical company - Says its pretax loss for the first half of 2025 remains largely unchanged from the year prior at €1.2 million, with no revenue generated in either year. Ovoca’s cash balance stands at €1.5 million as of June 30, down from €2.9 million on-year. Back in May, the company signed a conditional letter of intent to acquire Tadeen International Ltd, a UK company with ‘a portfolio of mineral exploration licenses in Morocco prospective for copper and silver’. Ovoca says it continues working to complete the purchase, and will update further ‘in due course’. ---------- Tissue Regenix PLC - Leeds, England-based regenerative medical devices firm - Posts lower revenue on-year after a first-half sales slump. Revenue declines 6.1% to $13.8 million from $14.7 million. Pretax loss for the six months ended June 30 widens significantly to $1.0 million from $63,000, while loss per share on continuing operations widens to 1.34 US cents from 0.54 cents. The firm’s cash position is $1.1 million as of June 30, compared to $1.9 million at the end of 2024. Earlier this month, Tissue Regenix noted a slowdown in orders from its partners due to macroeconomic uncertainty. Chief Executive Daniel Lee comments: ‘Although we have seen a downturn in trading in H1, with a resultant impact on our cash position, we remain confident in the underlying business and market opportunities for our leading products and superior technology. We expect both trading and cash to improve in the longer-term and our focus is to deliver sustainable revenue.’ --------- Solvonis Therapeutics PLC - London-based biopharmaceutical company focused on addiction and mental health disorders - Reports a pretax loss of £1.6 million for first half of 2025, widened from £469,000 the previous year. Its cash balance rises to £1.7 million as of June 30, from £27,000 on-year, while net assets at the end of June amounted to £6.9 , more than doubled from £3.1 million at the end of December. The firm hails the ‘transformational step’ of acquiring Awakn Life Sciences, a Canadian clinical-stage biotechnology firm, also focused on addiction and mental health, for a total purchase price of £3.7 million in May. Solvonis booked a £1.9 million loss on liabilities acquired though Awakn has added £5.6 million in total intangible assets. Solvonis says the integration process is underway, but it expects the enlarged company to continue to be loss-making ‘for the forseeable future’ as it remains pre-revenue. ---------- Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
